Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269462 | 0.88 | CA12 (0.60) | CA12CA1CA2TYRCA7 | |
| SCHEMBL641623 | 0.86 | CA12 (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL13958437 | 0.86 | CA12 (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL8782823 | 0.86 | ABCG2 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL142092 | 0.86 | ABCG2 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL641622 | 0.86 | CA12 (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL19244469 | 0.86 | ABCG2 (0.62) | CA12CA1CA2TYRCA7 | |
| SCHEMBL18569987 | 0.86 | GSK3B (0.60) | GSK3BKDM4ECYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL9339004 | 0.85 | CA12 (0.57) | CA12CA1CA2TYRCA7 | |
| SCHEMBL14634380 | 0.85 | CA12 (0.57) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322844-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322844-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-8273785-B2 | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273785-B2 | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110190366-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20110190366-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-7928136-B2 | Inhibitors of protein tyrosine kinase (PTK) receptors; diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis; 5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene)methyl)-N-hydroxy-2,4-dimethyl-1H-pyrrole-3-carboxamide | CURIS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928136-B2 | Inhibitors of protein tyrosine kinase (PTK) receptors; diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis; 5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene)methyl)-N-hydroxy-2,4-dimethyl-1H-pyrrole-3-carboxamide | CURIS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101641338-A | Multifunctional small molecules as antiproliferative agents | CURIS INC US | 2010-02-03 | — | — | CN | disclosed |
| CN-101535254-A | Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety | CURIS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080125478-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125478-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190366-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC2, HDAC1, BAZ2A | CA12 3428/4885CA1 2206/4885CA2 1563/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | CA12 3686/4885CA1 3759/4885CA2 2862/4885 |
| US-20080125478-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC2, HDAC1, BAZ2A | CA12 3428/4885CA1 2206/4885CA2 1563/4885 |
| US-20120322844-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC2, HDAC1, BAZ2A | CA12 3428/4885CA1 2206/4885CA2 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.